Kingfisher ups profit outlook as Screwfix offsets weak B&Q and France
(Alliance News) - Kingfisher PLC on Tuesday raised annual guidance, despite a "mixed" consumer environment, after reporting better-than-expected first half results. Read More
(Alliance News) - Kingfisher PLC on Tuesday raised annual guidance, despite a "mixed" consumer environment, after reporting better-than-expected first half results. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday: Read More
(Alliance News) - Stock prices in Europe were on the decline on Tuesday, returning some progress after the start of the week was supported by hope of diplomatic progress between the US and China. Read More
(Alliance News) - Andy Burnham will urge Brussels' top official Ursula von der Leyen not to use protectionist measures to freeze UK firms out of European contracts. Read More
(Alliance News) - Smiths Group reports an annual profit decline but reports it has kicked off a new buyback, while Kingfisher has lifted its guidance. Read More
Aimia Inc - Toronto-based conglomerate that owns rope-maker Cortland International Inc and invests in companies such as bus shelter advertising firm Clear Media Ltd - Sets date for listing on the AIM market in London for September 29, which is Tuesday next week. Aimia already has a primary listing on the Toronto Stock Exchange, and it has had a secondary listing on the Johannesburg Stock Exchange since February. It first announced plans to list in London late last month. Aimia doesn't provide any financial details for its initial public offering on AIM. Its shares closed at CAD2.72 in Toronto on Monday, giving the company a market capitalisation of CAD239.3 million, about GBP127.5 million. Read More
(Alliance News) - UK public sector borrowing was loftier than expected in August, data on Tuesday showed, on an increase in spending. Read More
(Alliance News) - World leaders including Donald Trump will be invited to Manchester next year as the UK hosts the G20 group of advanced economies. Read More
(Alliance News) - Stocks in London are set to open higher on Tuesday, building on Monday's solid advance, after US shares were lifted by artificial intelligence buzz overnight. Read More
(Alliance News) - Andy Burnham will insist the UK is not "on the slide" and attempt to draw a line under 10 years of post-Brexit turbulence as he makes his United Nations debut as UK prime minister. Read More
(Alliance News) - UK Prime Minister Andy Burnham has agreed to give military support to Saudi Arabia in its struggle against Houthi rebels in Yemen. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Monday and not separately reported by Alliance News: Read More
Coiled Therapeutics PLC - London-based clinical-stage oncology company - Says it has successfully enrolled patients across two escalation cohorts for the clinical development of its lipid-based formulation of brain-penetrant small-molecule TACC3 inhibitor AO-252. One cohort will be given a twice-daily 120 miligram dose, the other 160mg once a day. "All patients are progressing as planned through the assessment period, in accordance with the study protocol," Coiled says. Explains that the new formulation "is designed to achieve more consistent, dose-proportional absorption," in light of the 80% clinical benefit rate signal it observed in twice-daily tablet dosing. The dosages "were selected to optimise systemic drug exposure based on encouraging clinical activity observed with the original tablet formulation." Coiled says enrolment marks further progress towards its planned phase 1/2 dose-expansion cohorts in ovarian and prostate cancer. It aims to enrol up to 30 patients with the new formulation by the end of 2026, and also continues to expect initial safety and pharmacokinetic data readouts by the end of 2026. Read More